Antitumor activity of the immunomodulatory lead Cumaside

Int Immunopharmacol. 2010 Jun;10(6):648-54. doi: 10.1016/j.intimp.2010.03.003. Epub 2010 Mar 20.

Abstract

A new immunomodulatory lead Cumaside that is a complex of monosulfated triterpene glycosides from the sea cucumber Cucumaria japonica and cholesterol possesses significantly less cytotoxic activity against sea urchin embryos and Ehrlich carcinoma cells than the corresponding glycosides. Nevertheless Cumaside has an antitumor activity against different forms of experimental mouse Ehrlich carcinoma in vivo both independently and in combination with cytostatics. The highest effect occurs at a treatment once a day for 7 days before the tumor inoculation followed by Cumaside treatment once a day for 7 days. Prophylactic treatment with Cumaside and subsequent therapeutic application of 5-fluorouracil suppressed the tumor growth by 43%.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Ehrlich Tumor / drug therapy*
  • Cell Line, Tumor
  • Cholesterol / analogs & derivatives*
  • Cholesterol / chemistry
  • Cholesterol / therapeutic use
  • Female
  • Fluorouracil / therapeutic use
  • Glycosides / chemistry
  • Glycosides / therapeutic use*
  • Immunologic Factors / chemistry
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use*
  • Male
  • Mice
  • Saponins / therapeutic use
  • Triterpenes / chemistry
  • Triterpenes / therapeutic use*

Substances

  • Antineoplastic Agents
  • Glycosides
  • Immunologic Factors
  • Saponins
  • Triterpenes
  • cucumarioside A2-2
  • cumaside
  • Cholesterol
  • Fluorouracil